OMALIZUMAB
omalizumab 300 mg/2 mL injection, 2 mL pen device
OMALIZUMAB (14885K)
14885K
Manner of administration:Injection
Restriction
Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment - Initial 1 (New patients; or Recommencement of treatment in a new
treatment cycle following a break in PBS subsidised biological medicine therapy)
Restriction
Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment - Initial 2 (Change of treatment)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 7 | DPMQ: $418.14 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Xolair | |||||